Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 17/20 | 0.52 |
| ▸ | CA1 | P00915 | 16/20 | 0.52 |
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837449 | 1.00 | CA9 (0.52) | CA9CA1CA2CA12USP2 | |
| SCHEMBL9906193 | 0.95 | CA9 (0.49) | CA9CA1CA2CA12USP2 | |
| SCHEMBL9906260 | 0.95 | DNASE1L3 (0.51) | CA9CA1CA2CA12USP2 | |
| SCHEMBL13678642 | 0.94 | CA9 (0.49) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14526777 | 0.89 | CA9 (0.56) | CA9CA1CA2CA12USP2 | |
| SCHEMBL15432797 | 0.87 | CA9 (0.52) | CA9CA1CA2CA12USP2 | |
| SCHEMBL15372440 | 0.87 | CA9 (0.59) | CA9CA1CA2CA12USP2 | |
| SCHEMBL1688099 | 0.87 | FOLH1 (0.51) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14426887 | 0.86 | CA9 (0.39) | CA9CA1CA2CA12USP2 | |
| SCHEMBL9906320 | 0.86 | USP2 (0.54) | CA9CA1CA2CA12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190254973-A1 | COMBINING ORTHOGONAL CHEMISTRIES FOR PREPARATION OF MULTIPLEXED NANOPARTICLES | VERILY LIFE SCIENCES LLC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10203334-B2 | Methods and compositions related to nucleic acid binding assays | Nubad, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-1673399-B1 | DETECTING AND PROFILING MOLECULAR COMPLEXES | MONOGRAM BIOSCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160282357-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160282357-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9410186-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9410186-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9110075-B2 | Compositions for analyzing proteins | MONOGRAM BIOSCIENCES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9024022-B2 | Substrates of O6-alkylguanine-DNA alkyltransferase and mutants thereof | CIS BIO INTERNATIONAL (FR) | 2015-05-05 | — | — | US | disclosed |
| US-9024022-B2 | Substrates of O6-alkylguanine-DNA alkyltransferase and mutants thereof | CIS BIO INTERNATIONAL (FR) | 2015-05-05 | — | — | US | disclosed |
| US-8198031-B2 | Using epidermal growth factor receptor complexes to diagnose and prognose health in cancer patients; drug screening | MONOGRAM BIOSCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120088307-A1 | Methods and Compositions for Analyzing Proteins | MONOGRAM BIOSCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | CIS BIO INTERNATIONAL (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | CIS BIO INTERNATIONAL (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110014714-A1 | METHOD FOR SELECTIVE LABELING OF PROTEIN PRODUCED BY IN VITRO TRANSLATION BY USING A MARKER FROM TRNA PREPARED BY USING IN VITRO TRANSCRIPTION | INTRON BIOTECHNOLOGY, INC. (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20090173631-A1 | Single Cell Analysis of Membrane Molecules | ACLARA BIOSCIENCES, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20080311674-A1 | METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS | MONOGRAM BIOSCIENCES, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080233602-A1 | Detecting and profiling molecular complexes | MONOGRAM BIOSCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| US-7255999-B2 | Detection of preferential polypetide in sample; otain sample containing preferential polyeptide, electrophorese, incubate with probe, detect signal from probe and recover polypeptide | MONOGRAM BIOSCIENCES, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7160735-B2 | Tagged microparticle compositions and methods | MONOGRAM BIOSCIENCES, INC. (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190254973-A1 | COMBINING ORTHOGONAL CHEMISTRIES FOR PREPARATION OF MULTIPLEXED NANOPARTICLES | CD47, AGO2, EEA1 | CA9 3215/4885CA1 3496/4885CA2 4246/4885 |
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | OGG1, UNG, MPG | CA9 3630/4885CA1 4446/4885CA2 4139/4885 |
| US-20110014714-A1 | METHOD FOR SELECTIVE LABELING OF PROTEIN PRODUCED BY IN VITRO TRANSLATION BY USING A MARKER FROM TRNA PREPARED BY USING IN VITRO TRANSCRIPTION | TARBP1, NSUN3, TRMT1 | CA9 4854/4885CA1 4879/4885CA2 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.